• Vosevi contains three drugs: sofosbuvir, velpatasvir, and voxilaprevir. Epclusa contains only two drugs: sofosbuvir and velpatasvir.
• Vosevi may be used to treat chronic hepatitis C in adults with genotypes 1 to 6, with or without cirrhosis, who have been already treated with an HCV regimen containing an NS5A inhibitor.
• Epclusa may be used to treat chronic hepatitis C in adults with genotypes 1 to 6, with or without cirrhosis, regardless of whether they have had any prior treatment or not. In those with decompensated cirrhosis, it should be given in conjunction with ribavirin.
• Epclusa may also be used to treat chronic hepatitis C in children aged 3 years and older. Vosevi is only approved in adults.
• Cure rates are similar.
• Both Vosevi and Epclusa are manufactured by Gilead Sciences Inc.
• Vosevi and Epclusa are the same cost; approximately $930 per tablet.
• A 4-week treatment course of either Vosevi or Epclusa is approximately $26,026, an 8-week course is approximately $52,052 and a 12-week course is $78,078.
• Most insurance companies and Medicare cover the cost of Vosevi or Epclusa; however, you may have to meet certain criteria and there may be a copay.
• Gilead, the manufacturer of both Vosevi and Epclusa has a special patient assistance program called Support Path™ that may assist with co-pay insurance coupons or make Vosevi or Epclusa available at no charge for eligible and qualified uninsured patients
• There is currently no generic version of Vosevi or Epclusa.

Both Vosevi and Epclusa may be used to treat hepatitis C and both are manufactured by Gilead Sciences Ltd.

Vosevi contains three ingredients: sofosbuvir (400mg), velpatasvir (100mg), and voxilaprevir (100mg). It is usually given as a single dose once a day with food. Cure rates range from 91% to 100% depending on the HCV genotype and other factors (such as prior treatment).

Epclusa contains two ingredients: sofosbuvir (400mg) and velpatasvir (100mg). It is usually given as a single dose once daily with food. Cure rates range from 89% to 100% depending on the HCV genotype and other factors (such as prior treatment).

How much do Vosevi and Epclusa cost?

Both Vosevi and Epclusa are expensive.

According to the Drugs.com price guide which bases its price on the Drugs.com discount card which is accepted at most U.S. pharmacies the cost for Vosevi oral tablets is $930 each tablet (400mg/100mg/100mg) depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. This corresponds to an average cost of $26,026 for a 4-week treatment course, $52,052 for an 8-week treatment course, and $78,078 for a 12-week treatment course.

Epclusa also costs $930 for each tablet (eg, 400mg/100mg) depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. This corresponds to an average cost of $26,026 for a 4-week treatment course, $52,052 for an 8-week treatment course, and $78,078 for a 12-week treatment course.

Most insurance companies and Medicare cover the cost of Vosevi or Epclusa; however, you may have to meet certain criteria and you should always check with your insurance company first before you and your doctor make it your preferred treatment. There may also be a co-pay.

Gilead, the manufacturer of both Vosevi and Epclusa has a special patient assistance program called Support Path™ that may assist with co-pay insurance coupons or make Vosevi or Epclusa available at no charge for eligible and qualified uninsured patients insurance who need assistance paying for their out-of-pocket medication costs. To learn more about Support Path, call +1 855 769 72846, Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern Time).

If you have no success getting Vosevi or Epclusa at a reduced cost through Gilead’s Support Path, you could try organizations that offer help to people with hepatitis C, such as the American Liver Foundation, Hepatitis Foundation International, or Needy Meds.

What are Vosevi and Epclusa used for?

Vosevi may be used to treat chronic hepatitis C in adults with genotypes 1 to 6, with or without cirrhosis, who have been already treated with an HCV regimen containing an NS5A inhibitor. It may also be used to treat adults with HCV genotypes 1a or 4 that has previously been treated with a sofosbuvir regimen without an NS5A inhibitor.

Epclusa may be used to treat chronic hepatitis C in adults with genotypes 1 to 6, with or without cirrhosis. In those with decompensated cirrhosis, it should be given in conjunction with ribavirin. Epclusa may also be used to treat chronic hepatitis C in children aged 3 years and older.